Therefore, COX-2 inhibitors can block PGE-2 activity and, thus, reverse the PGE-2-created tumor immunosuppressive microenvironment, synergizing with oncolytic VACV for TME remolding [110], further confirming the benefit of COX-2 inhibitors and oncolytic VACV in combinations against tumors. This evidence concerns the gene PTGS2 and neoplasm.